Multisystem inflammatory syndrome in children in Canada.

Meghan Laverty, M. Salvadori, S. Squires, M. Ahmed, Lisa Eisenbeis, Santina J Lee, Annick Des Cormiers, Y. A. Li
{"title":"Multisystem inflammatory syndrome in children in Canada.","authors":"Meghan Laverty, M. Salvadori, S. Squires, M. Ahmed, Lisa Eisenbeis, Santina J Lee, Annick Des Cormiers, Y. A. Li","doi":"10.14745/ccdr.v47i11a03","DOIUrl":null,"url":null,"abstract":"This article provides a summary of the epidemiology of multisystem inflammatory syndrome in children (MIS-C) cases reported nationally in Canada by provincial and territorial health authorities. Multisystem inflammatory syndrome in children is a post-viral inflammatory syndrome that temporally follows coronavirus disease 2019 (COVID-19). Symptoms may include fever, abdominal pain, vomiting, diarrhea, skin rash and other signs of inflammation. In Canada, MIS-C is rare, with 269 cases reported to the Public Health Agency of Canada between March 11, 2020 and October 2, 2021. One hundred forty-two (53%) of these cases were lab-confirmed COVID-19 cases or epidemiologically-linked with COVID-19 cases. Cases have been reported in infants as young as one week to youth as old as 18 years, with a median age of six years. Cases were more likely to occur in males than females (58% vs 42%, respectively; p=0.006). Almost all MIS-C cases (99%) required hospitalization and 36% required intensive care unit admission. No deaths have been reported to date. The time trend of MIS-C aligns with the incidence rate time trend of COVID-19 reported in children, with a two to six-week lag.","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"17 1","pages":"461-465"},"PeriodicalIF":0.0000,"publicationDate":"2021-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canada communicable disease report = Releve des maladies transmissibles au Canada","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14745/ccdr.v47i11a03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

This article provides a summary of the epidemiology of multisystem inflammatory syndrome in children (MIS-C) cases reported nationally in Canada by provincial and territorial health authorities. Multisystem inflammatory syndrome in children is a post-viral inflammatory syndrome that temporally follows coronavirus disease 2019 (COVID-19). Symptoms may include fever, abdominal pain, vomiting, diarrhea, skin rash and other signs of inflammation. In Canada, MIS-C is rare, with 269 cases reported to the Public Health Agency of Canada between March 11, 2020 and October 2, 2021. One hundred forty-two (53%) of these cases were lab-confirmed COVID-19 cases or epidemiologically-linked with COVID-19 cases. Cases have been reported in infants as young as one week to youth as old as 18 years, with a median age of six years. Cases were more likely to occur in males than females (58% vs 42%, respectively; p=0.006). Almost all MIS-C cases (99%) required hospitalization and 36% required intensive care unit admission. No deaths have been reported to date. The time trend of MIS-C aligns with the incidence rate time trend of COVID-19 reported in children, with a two to six-week lag.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
加拿大儿童多系统炎症综合征。
本文概述了加拿大各省和地区卫生当局报告的儿童多系统炎症综合征(MIS-C)病例的流行病学。儿童多系统炎症综合征是冠状病毒病2019 (COVID-19)后暂时出现的病毒后炎症综合征。症状可能包括发烧、腹痛、呕吐、腹泻、皮疹和其他炎症迹象。在加拿大,misc很罕见,在2020年3月11日至2021年10月2日期间,向加拿大公共卫生署报告了269例病例。这些病例中有142例(53%)是实验室确诊的COVID-19病例或与COVID-19病例有流行病学关联。病例报告的婴儿小至一周,大至18岁,中位年龄为6岁。男性比女性更容易发生病例(分别为58%对42%;p = 0.006)。几乎所有MIS-C病例(99%)需要住院治疗,36%需要入住重症监护病房。到目前为止没有死亡报告。MIS-C的时间趋势与报告的儿童COVID-19发病率时间趋势一致,存在2至6周的滞后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Burden of disease of respiratory syncytial virus in older adults and adults considered at high risk of severe infection. Is there sufficient evidence to inform personal protective equipment choices for healthcare workers caring for patients with viral hemorrhagic fevers? Summary of the National Advisory Committee on Immunization (NACI) Statement-Updated guidance on Imvamune in the context of a routine immunization program. Surveillance of laboratory exposures to human pathogens and toxins, Canada, 2023. The prevalence of HIV pre-exposure prophylaxis (HIV-PrEP) use and HIV-PrEP-to-need ratio in nine Canadian provinces, 2018-2021.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1